For Patients

FOXFIRE Global is an international research study designed to evaluate a treatment option for patients with colorectal cancer that has undergone metastatic spread to the liver. The study completed recruitment at the end of 2014 and results are expected during 2017.

About the FOXFIRE Global Study

The study is designed to:

Compare the efficacy of treatment with SIRT using SIR-Spheres Y-90 resin microspheres plus chemotherapy (FOLFOX6m) versus chemotherapy (FOLFOX6m) alone in terms of overall survival (OS).

For Patients

The FOXFIRE Global study is no longer recruiting patients. If you have or have had colorectal cancer that has spread to the liver and your cancer cannot be treated with surgery at this time, you may talk with your doctor about further treatment options. 

About Selective Internal Radiation Therapy with SIR-Spheres Y-90 resin microspheres

Selective Internal Radiation Therapy (SIRT) is a form of treatment that has been designed to selectively deliver radiation to the cancer within the liver.

SIRT involves injecting very small radioactive particles known as SIR-Spheres Y-90 resin microspheres into the blood supply of the liver. The administration of SIR-Spheres Y-90 resin microspheres is a form of radiotherapy and is designed to destroy cancer in the liver. The SIR-Spheres Y-90 resin microspheres are administered via a small tube known as a catheter. This catheter is inserted into an artery in the patient's groin and then guided by the doctor to a position near the cancer in the liver. The SIR-Spheres Y-90 resin microspheres are then introduced directly into the blood supply of the liver following which they lodge in the small blood vessels of the liver tumours where they deliver their radiation directly to the tumours. In this clinical research study SIRT was given on the 3rd or 4th day of the first or second 'cycle' of chemotherapy.

More information on the treatment and patinet support can be found in the patient section of


SIR-Spheres registered trademark